IN

Incanthera plc

Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.

INC | Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BGL7YW15 (+1 more)
LEI:
2138002HEV4UFBOEXQ97
Country:
United Kingdom
Address:
C/O GATELEY LEGAL, M2 4WU MANCHESTER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Incanthera plc is a therapeutics company specializing in the fields of dermatology and oncology. The company focuses on discovering and developing targeted solutions and transformative treatment technologies to address unmet medical needs. It leverages unique formulation and delivery technologies for its product pipeline. Incanthera's current commercial focus is its proprietary skincare brand, SKIN + CELL, which offers dermatological applications developed from its core technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 12:15
Post-Annual General Meeting Information
AGM 2025 Presentation Materials
English 17.0 KB
2025-11-07 15:40
Post-Annual General Meeting Information
Result of AGM
English 32.4 KB
2025-11-06 08:30
Pre-Annual General Meeting Information
AGM 2025 Update
English 16.0 KB
2025-10-16 11:15
Investor Presentation
Proactive Investor Forum Presentation
English 18.0 KB
2025-10-14 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 20.7 KB
2025-08-11 08:00
Earnings Release
SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
English 21.4 KB
2025-08-06 08:00
Regulatory News Service
SKIN + CELL TO LAUNCH
English 24.3 KB
2025-07-09 08:00
Major Shareholding Notification
Holding(s) in Company
English 52.6 KB
2025-06-30 08:00
Share Issue/Capital Change
Subscription, Directors' Dealing and RPT
English 51.7 KB
2025-06-18 08:00
Environmental & Social Information
New Findings on Protective Effects of Skin + CELL
English 21.1 KB
2025-03-28 08:00
Regulatory News Service
Commercial Update
English 19.0 KB
2025-03-25 16:08
Legal Proceedings Report
Resolution of Allegations of Patent Infringement
English 19.3 KB

Automate Your Workflow. Get a real-time feed of all Incanthera plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Incanthera plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Incanthera plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
Nkarta, Inc. Logo
Developing off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America NKTX
NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea 182400
NLS Pharmaceutics Ltd. Logo
Developing therapies for rare CNS disorders, specializing in narcolepsy and sleep-wake issues.
United States of America NLSP
NovaBay Pharmaceuticals, Inc. Logo
Develops clinically-proven anti-infective therapies for eyecare, skincare, and wound care.
United States of America NBY
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France ALNOV
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland NOVN
NOVAVAX INC Logo
Develops and commercializes nanoparticle vaccines for serious infectious diseases.
United States of America NVAX
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea 229500

Talk to a Data Expert

Have a question? We'll get back to you promptly.